Jpmorgan Chase & CO Arcturus Therapeutics Holdings Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 272,007 shares of ARCT stock, worth $4.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
272,007
Previous 317,551
14.34%
Holding current value
$4.85 Million
Previous $10.7 Million
38.24%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ARCT
# of Institutions
189Shares Held
26.1MCall Options Held
320KPut Options Held
153K-
Federated Hermes, Inc. Pittsburgh, PA4.69MShares$83.6 Million0.28% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$47.2 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.28MShares$40.6 Million0.04% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.1MShares$37.4 Million0.46% of portfolio
-
Nikko Asset Management Americas, Inc.1.56MShares$27.9 Million0.44% of portfolio
About Arcturus Therapeutics Holdings Inc.
- Ticker ARCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,576,400
- Market Cap $474M
- Description
- Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...